Stories
Aurobindo Pharma Soars on US Launch of Novel Drug Adquey; Nuvama Predicts $300M Peak Sales
C
CNBC TV18•01-10-2026, 11:18
Aurobindo Pharma Soars on US Launch of Novel Drug Adquey; Nuvama Predicts $300M Peak Sales
- •Aurobindo Pharma launched Adquey, its first novel drug, in the US market, leading to a surge in its shares.
- •Adquey, a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, treats mild-to-moderate atopic dermatitis in adults and children aged two and above, with patent protection until 2036.
- •The launch marks Acrotech's entry into the US dermatology market, establishing a dedicated business unit to support Adquey and pursue further opportunities.
- •Nuvama projects Adquey could achieve peak sales of approximately $300 million, assigning an NPV of ’40 per share for the drug.
- •Nuvama maintains a "Buy" rating on Aurobindo Pharma with a target price of ’1,840, citing the company's expanding capabilities in higher-value products.
Key Questions Answered
Adquey is a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor used for treating mild-to-moderate atopic dermatitis in adults and children aged two years and older.
Brokerage Nuvama estimates that Adquey could achieve peak sales of around $300 million and has calculated a net present value of ₹40 per share for the drug.
Adquey was originally discovered by Otsuka Pharmaceutical and licensed to Aurobindo's arm Acrotech for US commercialisation.
